Lesinurad in combination with allopurinol: Results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1074-1080

  Perez Ruiz, Fernando ^a   Sundy, John S ^b,c   Miner, Jeffrey N ^d   Cravets, Matthew ^d,e   Storgard, Chris ^d  

^a HOSPITAL DE CRUCES   (Spain)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c GILEAD SCIENCES   (United States)

^d Ardea Biosciences Inc   (United States)

^e Receptos   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CREATININE; LESINURAD; PLACEBO; URATE; ANTIGOUT AGENT; THIOGLYCOLIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GOUT; HEADACHE; HEMATURIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TENDINITIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ALLOPURINOL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; THIOGLYCOLATES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84956659155     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207919     Document Type: Article

References (25)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-41.
2. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
3. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6:30-8.
4. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009;48(Suppl 2):ii2-8.
5. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46.
6. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
7. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
8. Perez-Ruiz F, Herrero-Beites AM. Evaluation and treatment of gout as a chronic disease. Adv Ther 2012;29:935-46.
9. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59-68.
10. KRYSTEXXA. Pegloticase. Bridgewater, NJ: Savient Pharmaceuticals, 2012.
11. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
12. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
13. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
14. Girardet JL, Miner JN. Urate crystal deposition disease and gout - new therapies for an old problem. In:Desai MC, ed. Annual reports in medicinal chemistry. Burlington: Elsevier, 2014:151-64.
15. Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol 2015;27: 164-9.
16. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
17. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306:711-20.
18. AFT. Probenecid. Auckland, New Zealand: AFT Pharmaceuticals, 2009.
19. Fam AG. Gout: excess calories, purines, and alcohol intake and beyond. Response to a urate-lowering diet. J Rheumatol 2005;32:773-7.
20. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
21. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012;125:679-87. e671.
22. Müller FO, Schall R, Groenewoud G, et al. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin Pharmacol 1993;44:69-72.
23. Iwanaga T, Kobayashi D, Hirayama M, et al. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 2005;33:1791-5.
24. Colin JN, Farinotti R, Fredj G, et al. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone. Eur J Clin Pharmacol 1986;31:53-8.
25. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32.